Get the Stockscreener App
18.20
2.02%
0.36
Centessa Pharmaceuticals Plc Adr stock is traded at $18.20, with a volume of 350.36K.
It is up +2.02% in the last 24 hours and up +5.08% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
See More
Previous Close:
$17.84
Open:
$17.87
24h Volume:
350.36K
Relative Volume:
0.58
Market Cap:
$2.35B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-11.67
EPS:
-1.56
Net Cash Flow:
$-160.51M
1W Performance:
+7.57%
1M Performance:
+5.08%
6M Performance:
+66.82%
1Y Performance:
+140.42%
1-Day Range:
$17.71
$18.50
1-Week Range:
$15.56
$18.50
52-Week Range:
$7.38
$18.97
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
18.20 | 2.35B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.63 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.52 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.75 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
Centessa Pharmaceuticals plc ADR (CNTA) Volatility Hits 6.67%: What Good Investors Need To Be Aware Of - Stocks Register
RLI Corp’s (RLI) Stock: A Week-by-Week Analysis - The News Heater
Real-Time Update: Desktop Metal Inc (DM) Stock Navigates the Market with Up-to-Date Data - The News Heater
Aon plc (AON) Stock: Evaluating the Market Performance - The News Heater
Qudian Inc ADR (QD) Stock: A Look at the Analyst Recommendations - The News Heater
Examining the Volatility of Costamare Inc’s (CMRE) Stock - The News Heater
Centessa Pharmaceuticals officer Tia Bush sells $185,406 in shares - Investing.com
Financial Fitness Check: Examining Magna International Inc (MGA)’s Key Ratios - The Dwinnex
Financial Metrics Exploration: Understanding Oncolytics Biotech, Inc (ONCY) Through Ratios - The Dwinnex
Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex
A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News
Centessa Pharmaceuticals chief business officer sells shares worth $193,429 - Investing.com
Centessa Pharmaceuticals general counsel Hussain Iqbal sells $91,740 in shares - Investing.com
Centessa Pharmaceuticals appoints new Chief Medical Officer - Investing.com
Centessa Pharmaceuticals' chief business officer sells shares worth $170,399 - Investing.com
Centessa Pharmaceuticals CEO sells $959,057 in shares - Investing.com India
Centessa Pharmaceuticals general counsel sells shares for $1.27 million By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals general counsel sells shares for $1.27 million - Investing.com
Stock Market Recap: Tencent Music Entertainment Group ADR (TME) Concludes at 11.30, a -5.68 Surge/Decline - The Dwinnex
Banzai International Inc (NASDAQ: BNZI): Getting A Free Pass? - Stocks Register
Metrics That Matter About Credo Technology Group Holding Ltd (NASDAQ: CRDO) - Stocks Register
Centessa Pharmaceuticals stock hits 52-week high at $18.77 By Investing.com - Investing.com UK
Centessa Pharmaceuticals CEO Saha Saurabh sells $5,450 in shares - Investing.com India
Centessa Pharmaceuticals' chief business officer sells $176,601 in shares - Investing.com
Centessa Pharmaceuticals CEO Saurabh sells shares worth $1.02 million - Investing.com India
Centessa Pharmaceuticals CEO Saurabh sells shares worth $1.02 million By Investing.com - Investing.com South Africa
Deutsche Bank initates Fidelity National Financial Inc (FNF) stock to a Hold - Knox Daily
Centessa Pharmaceuticals CEO sells shares worth $585,418 - Investing.com India
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update - GlobeNewswire Inc.
Endava PLC Sponsored ADR (DAVA) Beats Q1 Earnings Estimates - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Stock Moves -1.06%: What You Should Know - Yahoo Finance
Centessa Pharmaceuticals' chief business officer sells shares for $180,628 - Investing.com
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? - Yahoo Finance
Centessa Pharmaceuticals plcADR (CNTA) Price Target Increased by 14.58% to 11.22 - MSN
Centessa Pharmaceuticals CEO sells shares worth $863,727 - Investing.com
Are Finance Stocks Lagging Balfour Beatty PLC Sponsored ADR (BLFBY) This Year? - Yahoo Finance
Centessa Pharmaceuticals plc ADR (CNTA) expanding its growth trajectory ahead - SETE News
GSK Plc ADR [GSK] Insider Activity: An Update for Investors - Knox Daily
Centessa Pharmaceuticals plc ADR (CNTA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Analysts review Bilibili Inc ADR’s rating - Knox Daily
Centessa Pharmaceuticals plc ADR (CNTA) shows promising results - US Post News
Ratios Uncovered: Breaking Down Centessa Pharmaceuticals plc ADR (CNTA)’s Trailing Twelve Months Metrics - The Dwinnex
Centessa Pharmaceuticals executive sells over $260k in company stock - Investing.com India
Centessa Pharmaceuticals executive sells over $260k in company stock By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals plc ADR [CNTA] Shares Rise 2.15 % on Thursday - Knox Daily
Centessa Pharmaceuticals plc ADR (CNTA) is looking forward to a strong quarter - SETE News
Centessa's ORX142 shows promise for treating daytime sleepiness - Investing.com India
Sea Limited Sponsored ADR (SE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Monitoring Accenture plc (ACN) after recent insider movements - Knox Daily
ALLE stock rated an Underweight by Barclays - Knox Daily
Understanding the Risks of Investing in BranchOut Food Inc (BOF) - Knox Daily
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bush Tia L | Chief Technology & Quality Ofc |
Feb 03 '25 |
Sale |
16.86 |
11,000 |
185,406 |
121,503 |
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):